Why the study?
Does prior treatment with ramipril reduce long-term cardiovascular events and new diabetes diagnoses after trial cessation?
Population
4528 patients from 174 centers who agreed to further follow-up
Comparison
Ramipril vs Placebo. During post-trial follow-up, ACEI use…
Design
Cohort, Originally randomized in the HOPE trial
Follow-up
Additional 2.6 years post-trial
Loading...
May support legacy effects of ramipril after cessation; extends HOPE observations but remains hypothesis-generating and should not yet change practice.
Does prior treatment with ramipril reduce long-term cardiovascular events and new diabetes diagnoses after trial cessation?
The cardiovascular and metabolic benefits of ramipril observed during the HOPE trial are sustained for at least 2.6 years after trial cessation, despite similar subsequent ACEI use.
A 2005 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: